253 related articles for article (PubMed ID: 12452817)
1. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.
Akel S; Kolialexi A; Mavrou A; Metaxotou C; Loukopoulos D; Yataganas X
Clin Lab Haematol; 2002 Dec; 24(6):361-7. PubMed ID: 12452817
[TBL] [Abstract][Full Text] [Related]
2. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.
Yanagi M; Shinjo K; Takeshita A; Tobita T; Yano K; Kobayashi M; Terasaki H; Naoe T; Ohnishi K; Ohno R
Leukemia; 1999 Apr; 13(4):542-52. PubMed ID: 10214860
[TBL] [Abstract][Full Text] [Related]
3. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment.
Mühlmann J; Thaler J; Hilbe W; Bechter O; Erdel M; Utermann G; Duba HC
Genes Chromosomes Cancer; 1998 Feb; 21(2):90-100. PubMed ID: 9491319
[TBL] [Abstract][Full Text] [Related]
5. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Sick C; Schultheis B; Pasternak G; Kottke I; Hörner S; Heissig B; Hehlmann R
Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
Song YQ; Li W; Kong LH; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
[TBL] [Abstract][Full Text] [Related]
7. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
Reinhold U; Hennig E; Leiblein S; Niederwieser D; Deininger MW
Leukemia; 2003 Oct; 17(10):1925-9. PubMed ID: 14513039
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Takahashi N; Miura I; Kobayashi Y; Kume M; Yoshioka T; Otane W; Ohtsubo K; Takahashi K; Kitabayashi A; Kawabata Y; Hirokawa M; Nishijima H; Ichinohasama R; Decoteau J; Miura AB; Sawada K
Int J Hematol; 2005 Apr; 81(3):235-41. PubMed ID: 15814334
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis.
Cuneo A; Bigoni R; Emmanuel B; Smit E; Rigolin GM; Roberti MG; Bardi A; Piva N; Scapoli G; Castoldi G; Van Den Berghe H; Hagemeijer A
Leukemia; 1998 Nov; 12(11):1718-23. PubMed ID: 9823946
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
[TBL] [Abstract][Full Text] [Related]
11. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.
Lee YK; Lee DW; Kim YL; Lee S; Min CK; Kim YJ; Oh IH; Kim TG; Kim CC; Kim DW
Int J Hematol; 2002 Aug; 76(2):180-5. PubMed ID: 12215018
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocytes carry the fused bcr-abl gene in chronic myeloid leukaemia: a fluorescence in situ hybridization analysis from bone marrow biopsies.
Nolte M; Werner M; Ewig M; von Wasielewski R; Link H; Diedrich H; Georgii A
Virchows Arch; 1996 Mar; 427(6):561-5. PubMed ID: 8605566
[TBL] [Abstract][Full Text] [Related]
14. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
16. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
17. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
Leukemia; 2002 Jan; 16(1):53-9. PubMed ID: 11840263
[TBL] [Abstract][Full Text] [Related]
18. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
Itoh T; Tamura S; Takemoto Y; Kakishita E
Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
[TBL] [Abstract][Full Text] [Related]
19. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
20. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
